File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: A multivariate analysis by Cox regression in 141 patients
  • Basic View
  • Metadata View
  • XML View
TitleImpact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: A multivariate analysis by Cox regression in 141 patients
 
AuthorsChim, CS1
Sim, JP2
Chan, CC4
Kho, BC5
Chan, JC5
Wong, LG3
Law, M1
Liang, R1
Kwong, YL1
 
Keywordsessential thrombocythemia
JAK2
myeloid
thrombosis
transformation
 
Issue Date2010
 
PublisherManey Publishing. The Journal's web site is located at http://maney.co.uk/index.php/journals/hem/
 
CitationHematology, 2010, v. 15 n. 4, p. 187-192 [How to Cite?]
DOI: http://dx.doi.org/10.1179/102453309X12583347113933
 
AbstractObjective: To perform a multivariate analysis by Cox proportional hazard model of the impact of JAK2 V617F mutation on thrombosis and myeloid transformations in patients with essential thrombocythemia (ET). Patients and methods: The clinicopathologic features and outcome of a cohort of Chinese ET patients were retrospectively reviewed. JAK2 V617F mutation was detected by allele-specific polymerase chain reaction. Potential risk factors including JAK2 V617F that might impact on thrombosis and outcome were studied by multivariate analysis with Cox proportional hazard model. Results: Of 141 patients studied, JAK2 V617F was found in 80 cases (57%). JAK2 V617F was positively correlated with hemoglobin and leukocyte count at diagnosis. Univariate analysis showed significant thrombotic risks to be JAK2 V617F (P=0.006), hemoglobin >13 g/dl (P=0.015), and age >55 years (P=0.011). However, in multivariate analysis, only age and hemoglobin were independent risk factors. JAK2 V617F was unrelated to survival or leukemic/myelofibrotic transformation. Conclusion: In Chinese patients with ET, JAK2 V617F was positively associated with age, hemoglobin, and leukocyte count, but was not an independent risk for thrombosis. © 2010 W. S. Maney & Son Ltd.
 
ISSN1024-5332
2013 Impact Factor: 1.189
 
DOIhttp://dx.doi.org/10.1179/102453309X12583347113933
 
ISI Accession Number IDWOS:000280648600001
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChim, CS
 
dc.contributor.authorSim, JP
 
dc.contributor.authorChan, CC
 
dc.contributor.authorKho, BC
 
dc.contributor.authorChan, JC
 
dc.contributor.authorWong, LG
 
dc.contributor.authorLaw, M
 
dc.contributor.authorLiang, R
 
dc.contributor.authorKwong, YL
 
dc.date.accessioned2010-10-31T11:02:09Z
 
dc.date.available2010-10-31T11:02:09Z
 
dc.date.issued2010
 
dc.description.abstractObjective: To perform a multivariate analysis by Cox proportional hazard model of the impact of JAK2 V617F mutation on thrombosis and myeloid transformations in patients with essential thrombocythemia (ET). Patients and methods: The clinicopathologic features and outcome of a cohort of Chinese ET patients were retrospectively reviewed. JAK2 V617F mutation was detected by allele-specific polymerase chain reaction. Potential risk factors including JAK2 V617F that might impact on thrombosis and outcome were studied by multivariate analysis with Cox proportional hazard model. Results: Of 141 patients studied, JAK2 V617F was found in 80 cases (57%). JAK2 V617F was positively correlated with hemoglobin and leukocyte count at diagnosis. Univariate analysis showed significant thrombotic risks to be JAK2 V617F (P=0.006), hemoglobin >13 g/dl (P=0.015), and age >55 years (P=0.011). However, in multivariate analysis, only age and hemoglobin were independent risk factors. JAK2 V617F was unrelated to survival or leukemic/myelofibrotic transformation. Conclusion: In Chinese patients with ET, JAK2 V617F was positively associated with age, hemoglobin, and leukocyte count, but was not an independent risk for thrombosis. © 2010 W. S. Maney & Son Ltd.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationHematology, 2010, v. 15 n. 4, p. 187-192 [How to Cite?]
DOI: http://dx.doi.org/10.1179/102453309X12583347113933
 
dc.identifier.doihttp://dx.doi.org/10.1179/102453309X12583347113933
 
dc.identifier.epage192
 
dc.identifier.hkuros172846
 
dc.identifier.isiWOS:000280648600001
 
dc.identifier.issn1024-5332
2013 Impact Factor: 1.189
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid20670476
 
dc.identifier.scopuseid_2-s2.0-77955178851
 
dc.identifier.spage187
 
dc.identifier.urihttp://hdl.handle.net/10722/124931
 
dc.identifier.volume15
 
dc.languageeng
 
dc.publisherManey Publishing. The Journal's web site is located at http://maney.co.uk/index.php/journals/hem/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofHematology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsHematology. Copyright © Maney Publishing.
 
dc.subject.meshJanus Kinase 2 - genetics
 
dc.subject.meshLeukemia, Myeloid - etiology - genetics
 
dc.subject.meshPoint Mutation
 
dc.subject.meshThrombocythemia, Essential - complications - genetics - mortality - physiopathology
 
dc.subject.meshThrombosis - etiology - genetics
 
dc.subjectessential thrombocythemia
 
dc.subjectJAK2
 
dc.subjectmyeloid
 
dc.subjectthrombosis
 
dc.subjecttransformation
 
dc.titleImpact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: A multivariate analysis by Cox regression in 141 patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chim, CS</contributor.author>
<contributor.author>Sim, JP</contributor.author>
<contributor.author>Chan, CC</contributor.author>
<contributor.author>Kho, BC</contributor.author>
<contributor.author>Chan, JC</contributor.author>
<contributor.author>Wong, LG</contributor.author>
<contributor.author>Law, M</contributor.author>
<contributor.author>Liang, R</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<date.accessioned>2010-10-31T11:02:09Z</date.accessioned>
<date.available>2010-10-31T11:02:09Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Hematology, 2010, v. 15 n. 4, p. 187-192</identifier.citation>
<identifier.issn>1024-5332</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/124931</identifier.uri>
<description.abstract>Objective: To perform a multivariate analysis by Cox proportional hazard model of the impact of JAK2 V617F mutation on thrombosis and myeloid transformations in patients with essential thrombocythemia (ET). Patients and methods: The clinicopathologic features and outcome of a cohort of Chinese ET patients were retrospectively reviewed. JAK2 V617F mutation was detected by allele-specific polymerase chain reaction. Potential risk factors including JAK2 V617F that might impact on thrombosis and outcome were studied by multivariate analysis with Cox proportional hazard model. Results: Of 141 patients studied, JAK2 V617F was found in 80 cases (57%). JAK2 V617F was positively correlated with hemoglobin and leukocyte count at diagnosis. Univariate analysis showed significant thrombotic risks to be JAK2 V617F (P=0.006), hemoglobin &gt;13 g/dl (P=0.015), and age &gt;55 years (P=0.011). However, in multivariate analysis, only age and hemoglobin were independent risk factors. JAK2 V617F was unrelated to survival or leukemic/myelofibrotic transformation. Conclusion: In Chinese patients with ET, JAK2 V617F was positively associated with age, hemoglobin, and leukocyte count, but was not an independent risk for thrombosis. &#169; 2010 W. S. Maney &amp; Son Ltd.</description.abstract>
<language>eng</language>
<publisher>Maney Publishing. The Journal&apos;s web site is located at http://maney.co.uk/index.php/journals/hem/</publisher>
<relation.ispartof>Hematology</relation.ispartof>
<rights>Hematology. Copyright &#169; Maney Publishing.</rights>
<subject>essential thrombocythemia</subject>
<subject>JAK2</subject>
<subject>myeloid</subject>
<subject>thrombosis</subject>
<subject>transformation</subject>
<subject.mesh>Janus Kinase 2 - genetics</subject.mesh>
<subject.mesh>Leukemia, Myeloid - etiology - genetics</subject.mesh>
<subject.mesh>Point Mutation</subject.mesh>
<subject.mesh>Thrombocythemia, Essential - complications - genetics - mortality - physiopathology</subject.mesh>
<subject.mesh>Thrombosis - etiology - genetics</subject.mesh>
<title>Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: A multivariate analysis by Cox regression in 141 patients</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1024-5332&amp;volume=15&amp;issue=4&amp;spage=187&amp;epage=92&amp;date=2010&amp;atitle=Impact+of+JAK2V617F+mutation+on+thrombosis+and+myeloid+transformation+in+essential+thrombocythemia:+a+multivariate+analysis+by+Cox+regression+in+141+patients</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1179/102453309X12583347113933</identifier.doi>
<identifier.pmid>20670476</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77955178851</identifier.scopus>
<identifier.hkuros>172846</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77955178851&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>15</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>187</identifier.spage>
<identifier.epage>192</identifier.epage>
<identifier.isi>WOS:000280648600001</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Princess Margaret Hospital Hong Kong
  3. Tuen Mun Hospital
  4. Queen Elizabeth Hospital Hong Kong
  5. Pamela Youde Nethersole Eastern Hospital